v3.25.2
Note 2 - Summary of Significant Accounting Policies (Details Textual)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
USD ($)
shares
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
shares
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
Revenue from Contract with Customer, Including Assessed Tax $ 1,047,029   $ 812,770 $ 1,637,595 $ 1,623,260    
Research and Development Expense 590,121   61,616 688,519 131,880    
Restricted Cash, Current 0     0   $ 0  
Inventory, Finished Goods, Gross 6,040,410     6,040,410   6,428,806  
Inventory Valuation Reserves 1,184,731     1,184,731   12,429  
Inventory, Net 4,855,679     4,855,679   6,416,377  
Inventory Deposits $ 7,465,129     $ 7,465,129   $ 6,036,809  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares) | shares 977,250     977,250   564,126  
Class of Warrant or Right, Outstanding (in shares) | shares 147,039     147,039      
Maximum Insured Funds, FDIC and SPIC $ 750,000     $ 750,000      
Maximum Cash Insured 500,000     500,000      
Extra Insurance by SPIC, Cap, Unlimited Per Customer Securities 1,000,000,000     1,000,000,000      
Impairment, Long-Lived Asset, Held-for-Use       $ 0      
Number of Reportable Segments       3      
Goodwill, Impairment Loss 0 $ 10,103,048 0 $ 10,103,048 0 $ 0  
Goodwill 0     0   10,103,048 $ 9,583,836
Share-Based Payment Arrangement, Noncash Expense $ 40,479   $ 35,045 $ 587,055 $ 1,853,428    
Minimum [Member]              
Property, Plant and Equipment, Useful Life (Year) 3 years     3 years      
Finite-Lived Intangible Asset, Useful Life (Year) 3 years     3 years      
Maximum [Member]              
Property, Plant and Equipment, Useful Life (Year) 5 years     5 years      
Finite-Lived Intangible Asset, Useful Life (Year) 10 years     10 years      
Nonrelated Party [Member]              
Accounts Receivable, before Allowance for Credit Loss, Current $ 846,982     $ 846,982   1,031,972  
Accounts Receivable, Allowance for Credit Loss, Current 406,690     406,690   15,306  
Accounts Receivable, after Allowance for Credit Loss 440,292     440,292   1,016,666  
Related Party [Member]              
Accounts Receivable, before Allowance for Credit Loss, Current 2,195,880     2,195,880   1,000,000  
Accounts Receivable, Allowance for Credit Loss, Current 40,633     40,633   6,700  
Accounts Receivable, after Allowance for Credit Loss 2,155,247     2,155,247   $ 993,300  
Electric Vehicles [Member]              
Revenue from Contract with Customer, Including Assessed Tax       348,063      
Medical Supplies [Member]              
Revenue from Contract with Customer, Including Assessed Tax       $ 1,289,532      
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Electric Vehicles [Member]              
Number of Major Customers       2      
Concentration Risk, Percentage       100.00%      
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Medical Supplies [Member]              
Number of Major Customers       1      
Concentration Risk, Percentage       100.00%      
Customer Concentration Risk [Member] | Accounts Receivable [Member]              
Number of Major Customers       5      
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Five Customers [Member]              
Concentration Risk, Percentage       93.00%      
Supplier Concentration Risk [Member] | Deposits Outstanding [Member] | One Customer [Member]              
Concentration Risk, Percentage       100.00%      
Lender Concentration Risk [Member] | Liabilities, Total [Member]              
Number of Major Vendors with Accounts Payable       3   2  
Lender Concentration Risk [Member] | Liabilities, Total [Member] | Three Vendors [Member]              
Concentration Risk, Percentage       60.00%   50.00%  
Delivery of Medical Supplies [Member]              
Revenue from Contract with Customer, Including Assessed Tax $ 1,072,266            
Delivery of Medical Supplies [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]              
Number of Major Customers 1            
Concentration Risk, Percentage 100.00%            
Vehicle Sales [Member]              
Revenue, Net       $ (25,237)      
Vehicle Sales [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]              
Number of Major Customers 1            
Concentration Risk, Percentage 100.00%            
Revision of Prior Period, Error Correction, Adjustment [Member]              
Revenue from Contract with Customer, Including Assessed Tax   $ 0          
Research and Development Expense $ 400,000            
Revision of Prior Period, Error Correction, Adjustment [Member] | Delivery of Medical Supplies [Member]              
Revenue from Contract with Customer, Including Assessed Tax $ 126,535